



August 1, 2017

## Cumberland Pharmaceuticals To Announce Second Quarter 2017 Financial Results

NASHVILLE, Tenn., Aug. 1, 2017 /PRNewswire/ -- **Cumberland Pharmaceuticals Inc.** (NASDAQ: CPIX) announced today that it will release second quarter 2017 financial results after the market closes on Tuesday, August 8, 2017. A conference call and live Internet webcast will be held on Tuesday, August 8, 2017, at 4:30 p.m. Eastern Time to discuss the results.



To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers). A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 855-859-2056 (for U.S. callers) or 404-537-3406 (for international callers). The Conference ID for the rebroadcast is 48389040. The live webcast and rebroadcast can be accessed via Cumberland's website at <http://investor.shareholder.com/cpix/events.cfm>.

**Cumberland Pharmaceuticals Inc.** is a specialty pharmaceutical company focused on acquisition, development, and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's seven marketed products include Acetadote<sup>®</sup> (*acetylcysteine*) Injection for the treatment of acetaminophen poisoning, Caldolor<sup>®</sup> (*ibuprofen*) Injection, for the treatment of pain and fever, Kristalose<sup>®</sup> (*lactulose*) for Oral Solution, a prescription laxative, Vaprisol<sup>®</sup> (*conivaptan*) Injection, for the treatment of hyponatremia and Omeclamox-Pak<sup>®</sup> for the treatment of *H. pylori* infection and duodenal ulcer disease, Ethyol<sup>®</sup> (*amifostine*) for Injection, for the treatment of oncology patients, and Totect<sup>®</sup> (*dexrazoxane*) for injection, an oncology support product. Cumberland is developing Hepatoren<sup>®</sup> (*ifetroban*) Injection for the treatment of Hepatorenal Syndrome, Boxaban<sup>®</sup> (*ifetroban*) Oral Capsule for the treatment of Aspirin-Exacerbated Respiratory Disease, Vasculan<sup>™</sup> (*ifetroban*) Oral Capsule for the treatment of systemic sclerosis, and Portaban<sup>™</sup>, for the treatment of portal hypertension. Cumberland is dedicated to providing innovative products that improve quality of care for patients. For more information on Cumberland's approved products, including full prescribing information, please visit the individual product websites, links to which can be found on the Company's website at [www.cumberlandpharma.com](http://www.cumberlandpharma.com).

View original content:<http://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-to-announce-second-quarter-2017-financial-results-300497317.html>

SOURCE Cumberland Pharmaceuticals Inc.

News Provided by Acquire Media